Azenta (NASDAQ:AZTA) Reaches New 12-Month High on Strong Earnings

Azenta, Inc. (NASDAQ:AZTA)’s stock price hit a new 52-week high on Wednesday following a better than expected earnings announcement. The stock traded as high as $47.72 and last traded at $47.4580, with a volume of 204,979 shares. The stock had previously closed at $40.48.

The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.17. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. The company had revenue of $167.09 million during the quarter, compared to analysts’ expectations of $160.16 million.

Azenta News Roundup

Here’s some of the latest news about AZTA:

• Positive Sentiment: For fiscal Q4 2026, Azenta reported adjusted EPS of $0.28, versus analysts’ $0.11 estimate, and revenue of $167.09 million, above the $160.16 million consensus. Revenue grew 5% year over year as reported and 2% organically. Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026
• Positive Sentiment: Fiscal 2027 revenue guidance of $648 million to $660 million is above the $632.4 million consensus. Azenta also expects 3%–5% organic revenue growth and adjusted EBITDA margin expansion of about 200–250 basis points, signaling expectations for continued growth and improved profitability. Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims tied to allegations that Azenta may have provided materially misleading business information. The inquiry could create legal and reputational uncertainty, but the announcement describes allegations, not a finding of misconduct. Rosen Law Firm investigation announcement

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AZTA. Needham & Company LLC restated a “buy” rating and set a $37.00 target price on shares of Azenta in a report on Monday, September 14th. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a report on Sunday, October 18th. Finally, Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 26th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $41.20.

Institutional Investors Weigh In On Azenta

Several large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in Azenta during the second quarter worth about $2,453,000. Hsbc Holdings PLC bought a new stake in shares of Azenta in the second quarter worth about $1,108,000. Jupiter Topco LLC bought a new stake in shares of Azenta in the second quarter worth about $435,000. Bank of America Corp DE bought a new stake in shares of Azenta in the second quarter worth about $17,058,000. Finally, Man Group plc acquired a new stake in shares of Azenta during the second quarter worth about $9,402,000. Institutional investors own 99.08% of the company’s stock.

Azenta Price Performance

The company has a market cap of $2.08 billion, a price-to-earnings ratio of -17.18 and a beta of 1.47. The stock has a 50-day moving average price of $35.64 and a 200 day moving average price of $28.47.

About Azenta

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.